Fig 1.
GTX-104 drug delivery technology.
Fig 2.
The Overall Study flowchart.
Fig 3.
Schematic drawing of the timeline of the study.
Table 1.
Definitions of Hypotension and Heart Rate Abnormalities.
Table 2.
Demographic Characteristics.
Table 3.
Pharmacokinetic Parameters (Geometric Least Square Means) for Primary Endpoints.*.
Fig 4.
Mean Plasma Nimodipine Concentration after First Dose.
Mean ± standard deviation of plasma nimodipine concentration after the first dose of intravenous GTX-104 (4 mg bolus, n = 56) and oral nimodipine capsules (60 mg, n = 55).
Fig 5.
Mean Plasma Nimodipine Concentration after Each Dose on Day 3.
Mean ± standard deviation of plasma nimodipine concentration after each of the 6 doses of intravenous GTX-104 (4 mg boluses, n = 56) and oral nimodipine capsules (60 mg, n = 55).
Table 4.
Tmax for first dose on Day 1 and for all doses on Day 3.
Table 5.
Overview of Adverse Events.
Table 6.
Treatment Emergent Adverse Events by Medical Dictionary for Regulatory Activities Preferred Term and System Organ Class.
Table 7.
Summary of Vital Sign Interpretation by Treatment.